Perpetual Ltd Has $12.28 Million Stake in LivaNova PLC (NASDAQ:LIVN)

Perpetual Ltd grew its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 3.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 219,528 shares of the company’s stock after purchasing an additional 6,436 shares during the period. Perpetual Ltd owned about 0.41% of LivaNova worth $12,280,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Headlands Technologies LLC grew its holdings in LivaNova by 33.3% during the fourth quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after buying an additional 451 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of LivaNova in the third quarter valued at about $217,000. Teza Capital Management LLC bought a new position in shares of LivaNova during the third quarter valued at about $275,000. Aigen Investment Management LP purchased a new stake in LivaNova in the 4th quarter valued at about $286,000. Finally, WINTON GROUP Ltd bought a new position in shares of LivaNova during the 3rd quarter worth approximately $327,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Trading Up 4.1 %

LIVN opened at $55.63 on Friday. The company has a current ratio of 3.17, a quick ratio of 2.71 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $57.69 and a 200-day moving average price of $53.72. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The business had revenue of $294.90 million during the quarter, compared to analyst estimates of $278.17 million. During the same period in the previous year, the business earned $0.43 EPS. LivaNova’s revenue was up 12.0% compared to the same quarter last year. As a group, analysts predict that LivaNova PLC will post 2.59 EPS for the current year.

Insider Activity

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the transaction, the director now owns 27,534 shares in the company, valued at approximately $1,655,068.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LIVN. Barclays boosted their price objective on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Robert W. Baird raised their price objective on shares of LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Mizuho boosted their target price on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Finally, Needham & Company LLC restated a “buy” rating and set a $72.00 price target on shares of LivaNova in a research note on Thursday, June 6th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, LivaNova presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.